$MLNT

M

mr_byte31

$MLNT was surging on 19.06.2019 by 223% due to the following reason :

Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia
More...

Melinta Therapeutics' stock rockets on heavy volume after FDA accepts sNDA for Baxdela
More...

I checked the FDA website approvals but I couldn't find any info about this approval on the same date that the stock rockets.

I only found outdated approvals for this company on 19.06.2017

does anybody know how can I get the new approvals from FDA website or any official website ?

I don't like to use yahoofinance , stockalpha , ... etc for such thing since they sometimes provide rumors !
 
mr_byte31 said:
$MLNT was surging on 19.06.2019 by 223% due to the following reason :





I checked the FDA website approvals but I couldn't find any info about this approval on the same date that the stock rockets.

I only found outdated approvals for this company on 19.06.2017

does anybody know how can I get the new approvals from FDA website or any official website ?

I don't like to use yahoofinance , stockalpha , ... etc for such thing since they sometimes provide rumors !
More...
check this website https://www.biopharmcatalyst.com/calendars/fda-calendar
 
Interesting. My test bot shorted this thing yesterday at $6.61 and covered today at $5.03, for 23% profit. And right then I see this post.
Anyway, it didn’t take a genius to figure out how to play this, unless my bot is a genius, haha.
 
guru said:
Interesting. My test bot shorted this thing yesterday at $6.61 and covered today at $5.03, for 23% profit. And right then I see this post.
Anyway, it didn’t take a genius to figure out how to play this, unless my bot is a genius, haha.
More...
The stock was over extended.
the problem in this stocks it is very hard to borrow !
if my broker allow me , I would short it on the close of its 223%

I am not looking here for strategy. I am searching for the news on the FDA so I can find the news !
 
mr_byte31 said:
The stock was over extended.
the problem in this stocks it is very hard to borrow !
if my broker allow me , I would short it on the close of its 223%

I am not looking here for strategy. I am searching for the news on the FDA so I can find the news !
More...

Understood. Just saw it here right after my test trade was closed, but in practice I wouldn’t be able to short borrow.
I’d hope FDA does update or provide some info soon, or maybe you could call them since they may like to know if a company is providing false info...
 
guru said:
Understood. Just saw it here right after my test trade was closed, but in practice I wouldn’t be able to short borrow.
I’d hope FDA does update or provide some info soon, or maybe you could call them since they may like to know if a company is providing false info...
More...
what broker did you use for short ?
 
SalehTrade said:
check official website for company http://ir.melinta.com/press-releases
More...
Thanks for the link.
I could find my answer :
The FDA granted priority review status based on the previous Qualified Infectious Disease Product (QIDP) designation, which provides certain incentives for the development of antibacterial and antifungal treatments for serious or life-threatening infections. Through this process, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date (proposed review deadline) of October 24, 2019.
More...

seems not approval on the drug but just a priority to review it.
people on stock market was exaggerating about the news !
 
You must log in or register to reply here.
Back
Top